Loading data for BTAI — first visit, this takes a few seconds.

Alerta

BioXcel Therapeutics Inc. (BTAI)

NasdaqCM: BTAI · Precio en tiempo real · USD

1.06

+0.13 (13.98%)

Al cierre: Aug 12, 2026, 8:00 PM

13.98% (1D)

No hay datos disponibles

Precio de compra	0.75
Capitalización de mercado	32.73M
Ingresos (TTM)	680K
Beneficio neto (TTM)	-75.33M
Beta	0.29
EPS (TTM)	-5.37
Ratio PER (TTM)	n/a
Adelante PE	-0.69
P/B (TTM)	-0.27
P/S (TTM)	48.13
Earnings Date	Mar 26, 2026

Precio de venta	1.26
Volumen	1,104,001
Volumen medio (20D)	906,564
Abierto	0.96
Anterior Cerrar	0.93
Rango del día	0.96 - 1.09
Rango de 52 semanas	0.74 - 6.85
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501...

[Leer más]

Industria Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Fecha Mar 8, 2018

Empleados 29

Bolsa de Valores NasdaqCM

Símbolo bursátil BTAI

Sitio web https://www.bioxceltherapeutics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de BioXcel Therapeutics fueron 642K, una disminución de -71.67% en comparación con 2.27M del año anterior. Las ganancias fueron -69.9M, un aumento de 17.28%.

Estados financieros

Sorpresa de resultados

BioXcel Therapeutics ha publicado sus resultados trimestrales en May 15, 2026:

Ingresos de $206K falla las estimaciones por $0, con 22.62% Crecimiento interanual.

EPS de -0.54 falla las estimaciones por -0.06, con 84.83% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que BioXcel Therapeutics Inc. publique sus resultados el Mar 26, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 meses hace · Zacks

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock

BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 meses hace · Zacks

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3 meses hace · Zacks

CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3 meses hace · Zacks

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Página 1 de 2

BioXcel Therapeutics Inc. (BTAI)